Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis

Psoriatic arthritis (PsA) is a chronic inflammatory autoimmune disease that can adversely affect functional capabilities, if left untreated, leading to irreparable damage to joint spaces [ [1] McInnes I.B. Mease P.J. Kirkham B. et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 386: 1137-1146https://doi.org/10.1016/S0140-6736(15)61134-5 Abstract Full Text Full Text PDF PubMed Scopus (694) Google Scholar ]. Secukinumab, a biologic agent antagonizing the interleukin-17A (IL-17A) receptor, approved by the Food and Drug Administration (FDA) in 2015, has been indicated for the treatment of moderate to severe plaque psoriasis and active PsA [ [1] McInnes I.B. Mease P.J. Kirkham B. et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 386: 1137-1146https://doi.org/10.1016/S0140-6736(15)61134-5 Abstract Full Text Full Text PDF PubMed Scopus (694) Google Scholar ]. When compared with the general population, patients with PsA present with decreased quality-of-life and impairment of functional capacity. Hence for the treatment of this chronic condition, a comprehensive and effective clinical approach must use drugs with superior tolerability and efficacy over the long term. The availability of sufficient trial data for long-term outcomes of secukinumab at 52 weeks warrants a meta-analysis of randomized clinical trials (RCTs). Thus, we sought to conduct this systemic review and meta-analysis to compare the efficacy and safety of secukinumab for long-term outcomes, which include maintenance of remission of joint and skin disease, resolution of enthesitis and dactylitis, and adverse effects.